Cost Minimization Analysis of Insulin Glargine 300 U/Ml Vs Glargine 100 U/Ml for the Management of Type 2 Diabetes from A Private and Public Third-Party Payer Perspective in Chile

May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.506
https://www.valueinhealthjournal.com/article/S1098-3015(18)30806-4/fulltext
Section Title :
Section Order : 1312
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30806-4&doi=10.1016/j.jval.2018.04.506
HEOR Topics :
Tags :
Regions :